• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Nephros Inc.

    2/3/23 3:13:44 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care
    Get the next $NEPH alert in real time by email
    SC 13G 1 s22-22830b_cowen13g.htm

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. ___)*

    Nephros, Inc.
    (Name of Issuer)
    Common Stock
    (Title of Class of Securities)
    640671400
    (CUSIP Number)
    December 31, 2022
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [X] Rule 13d-1(b)

     

    [_] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Page 1 of 6

     

     

     

    SCHEDULE 13G

    CUSIP No. 640671400

     

    1 Names of Reporting Persons
    Cowen Prime Advisors LLC
    2 Check the appropriate box if a member of a Group (see instructions)
    (a)  [ ]
    (b)  [x]
    3 SEC Use Only
     
    4 Citizenship or Place of Organization
    Delaware Limited Liability Company

    Number of Shares Beneficially Owned by Each Reporting Person With:

     

    5 Sole Voting Power
    0
    6 Shared Voting Power
    0
    7 Sole Dispositive Power
     0
    8 Shared Dispositive Power
    0
    9 Aggregate Amount Beneficially Owned by Each Reporting Person
    0
    10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
    N/A
    11 Percent of class represented by amount in row (9)
    0
    12 Type of Reporting Person (See Instructions)
    IA
           

     

    Page 2 of 6

     

     

    Item 1.

    (a)       Name of Issuer: Nephros Inc.

    (b)       Address of Issuer’s Principal Executive Offices: 380 Lackawanna Place, South Orange, NJ 07079

    Item 2.

    (a)Name of Person Filing: Cowen Prime Advisors LLC
    (b)Address of Principal Business Office or, if None, Residence: 599 Lexington Avenue, Floor 21, New York, NY 10022
    (c)Citizenship: Delaware Limited Liability Corporation
    (d)Title and Class of Securities: Common Stock
    (e)CUSIP No.: 640671400
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)[_] Broker or dealer registered under Section 15 of the Act;
    (b)[_] Bank as defined in Section 3(a)(6) of the Act;
    (c)[_] Insurance company as defined in Section 3(a)(19) of the Act;
    (d)[_] Investment company registered under Section 8 of the Investment Company Act of 1940;
    (e)[x] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
    (f)[_] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
    (g)[_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
    (h)[_] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)[_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
    (j)[_] A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
    (k)[_] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    Page 3 of 6

     

     

    Item 4.Ownership
    (a)Amount Beneficially Owned: 0.00 See also, NOTES 1, 2, 3 and 4, below.

    (b)       Percent of Class: 0

    (c)       Number of shares as to which such person has:

    (i)       Sole power to vote or to direct the vote: 0

    (ii)       Shared power to vote or to direct the vote: 0

    (iii)Sole power to dispose or to direct the disposition of: 0
    (iv)Shared power to dispose or to direct the disposition of: 0.00 . See also, NOTE 1, 2, 3 and 4, below.

     

    NOTE 1: Cowen Prime Advisors LLC (“CPA”) is a registered investment adviser under the Investment Advisers Act of 1940. In its role as investment adviser, CPA possesses discretionary investment authority to determine the identity and amount of securities to be bought and sold, including the securities reported in this schedule. All securities reported in this schedule are owned by various clients, who have retained sole proxy voting authority over all of the shares. However, CPA has sole authority to dispose of the position as appropriate. The filing of this Schedule 13G should not be construed as an admission that CPA or any of its affiliates is the beneficial owner of any securities covered by this Schedule 13G for any purpose other than filings required to be made under Section 13(d) of the Securities Exchange Act of 1934 and related rules.

    NOTE 2: CPA reported this issuer and the same total number of shares beneficially owned by CPA as discretionary investment manager in the Information Table filed by CPA as part of its 4th quarter 2022 Form 13F filing. Source used for Shares Outstanding is Q4 2022 10-Q.

     

    NOTE 3: Mr. Andrew Wiener, one of the portfolio managers of the CPA Samjo Investment Program (“SI”), is also the sole Managing Member of Samjo Capital, LLC and Samjo Management, LLC which serve as the General Partner and Management Company, respectively, of Samjo Partners, LP, an investment partnership (hedge fund) and HAFF Partners LP, a family investment partnership, both of which employ investment strategies that are similar to those employed in the CPA SI program. Samjo Capital, LLC, Samjo Management, LLC, Samjo Partners, LP and HAFF Partners LP are not affiliated with CPA. Mr. Wiener, along with his fellow CPA SI portfolio managers identified below, is responsible for the decision to invest client accounts of CPA SI in shares of this issuer. In addition to Mr. Wiener’s portfolio management responsibilities for CPA SI, Mr. Wiener may invest, and from time to time has, invested assets of his non-CPA clients in shares of this same issuer.  However, because these non-CPA clients are an unaffiliated outside business activity of Mr. Wiener over which CPA has no control or other relationship, CPA does not make joint filings with respect to any shares of the issuer held by any non-CPA clients. To the best of CPA’s knowledge and belief, Mr. Wiener reports the ownership of shares by such non-CPA clients separately to the extent required and is identified as the reporting person.

     

    Mr. David Drucker is one of the portfolio managers of the CPA SI program.  Mr. Drucker shares investment discretion with Mr. Wiener with respect to the decision to invest client accounts of CPA SI in shares of this issuer.

     

    Page 4 of 6

     

     

     

    Mr. Irwin Silverberg is the portfolio managers of CPA I.S. Value Program (“ISV”).  Mr. Silverberg shares investment discretion with Mr. Bernstein with respect to the decision to invest client accounts of CPA ISV in shares of this issuer.

     

    Mr. Jeffrey Bernstein is one of the portfolio managers of CPA I.S. Value Program (“ISV”). Mr. Bernstein shares investment discretion with Mr. Silverberg with respect to the decision to invest client accounts of CPA ISV in shares of this issuer.

     

    NOTE 4: In July 2021, Cowen Prime Advisors LLC filed a Succession By Amendment to Cowen Prime Services LLC.  Cowen Prime Advisors LLC is now a stand-alone SEC Registered Advisor and Regulatory Filings (Form 13F, Form 13G, etc.) will be reflected accordingly.  In August 2021, Cowen Prime Services LLC merged with Cowen and Company, LLC and Form BDW was approved December 2021.  Cowen Prime Services LLC is no longer a registered broker-dealer or registered advisor.

     

    Item 5.Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

    Item 6.Ownership of more than Five Percent on Behalf of Another Person.

    The securities as to which this Schedule is filed by CPA, in its capacity as investment adviser, are owned of record by individual clients. The clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. To the best of CPA’s knowledge and belief, no such client is known to have such right or power with respect to more than five percent of this class of securities. The filing of this statement shall not be construed as an admission that CPA is, for the purposes of sections 13(d) or 13(g) of the Act, the beneficial owner of any securities covered by the statement.

    Item 7.Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

    Not applicable

    Item 8.Identification and classification of members of the group.

    Not applicable

    Item 9.Notice of Dissolution of Group.

    Not applicable

    Item 10.Certifications.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

     

    Page 5 of 6

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated:  

    /s/ Signature

    Robert E. Moore

    MD/Global Head of Prime Brokerage Trading

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

    Page 6 of 6 

    Get the next $NEPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NEPH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NEPH
    Financials

    Live finance-specific insights

    See more
    • Nephros Announces Financial Results for Quarter Ended September 30, 2024

      Third-Quarter Net Revenue of $3.5 Million;Operational Improvements Result In First Profitable Quarter SOUTH ORANGE, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the third quarter ended September 30, 2024. Financial Highlights* Net income of $0.2 million, compared to a net loss of $0.2 millionAdjusted EBITDA of $295,000, compared to $11,000Net revenue of $3.5 million, an 8% increase over Q2 2024; a decrease of 6% over Q3 prior year *Stated performance is relative to same period in the prior year unless otherwise no

      11/7/24 4:01:00 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Schedules Third Quarter 2024 Financial Results Conference Call

      SOUTH ORANGE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions for both healthcare and commercial markets, today announced that it will file its third-quarter financial results on Thursday, November 7, 2024 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows:Domestic access: 1 (844) 808-7106International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page. Alternatively, a repl

      10/31/24 7:30:00 AM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Announces Financial Results for Quarter Ended June 30, 2024

      Second-Quarter Net Revenue of $3.3 Million; New Accounts Help Drive Growth in Core Programmatic Business SOUTH ORANGE, NJ, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the second quarter ended June 30, 2024. Financial Highlights* Net revenue of $3.3 million, a decrease of 8% over Q2 prior year; programmatic revenue (excluding emergency response revenue) increased 8% over Q2 prior yearNet loss of $0.3 million, compared to a net loss of $0.4 millionAdjusted EBITDA of ($133,000), compared to ($183,000) *Stated performance

      8/8/24 4:01:00 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care

    $NEPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley FBR initiated coverage on Nephros with a new price target

      B. Riley FBR initiated coverage of Nephros with a rating of Buy and set a new price target of $12.50

      1/26/21 6:12:57 AM ET
      $NEPH
      Medical/Dental Instruments
      Health Care

    $NEPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nephros to Participate in the Benchmark Company Annual Discovery One-on-One Investor Conference on December 11, 2024 in NYC

      SOUTH ORANGE, N.J., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will be participating in the Benchmark Company 13th Annual Discovery One-on-One Investor Conference. The event is scheduled for Wednesday, December 11, 2024, at the New York Athletic Club in New York City. Robert Banks, CEO and Judy Krandel, CFO of Nephros, Inc. will be hosting one-on-one and group investor meetings. If you would like to schedule a 1x1 investor meeting please make sure you are registered here: The conference offers emerging growth and dynamic publicly traded comp

      12/4/24 9:00:00 AM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Announces Financial Results for Quarter Ended September 30, 2024

      Third-Quarter Net Revenue of $3.5 Million;Operational Improvements Result In First Profitable Quarter SOUTH ORANGE, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the third quarter ended September 30, 2024. Financial Highlights* Net income of $0.2 million, compared to a net loss of $0.2 millionAdjusted EBITDA of $295,000, compared to $11,000Net revenue of $3.5 million, an 8% increase over Q2 2024; a decrease of 6% over Q3 prior year *Stated performance is relative to same period in the prior year unless otherwise no

      11/7/24 4:01:00 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Schedules Third Quarter 2024 Financial Results Conference Call

      SOUTH ORANGE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions for both healthcare and commercial markets, today announced that it will file its third-quarter financial results on Thursday, November 7, 2024 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows:Domestic access: 1 (844) 808-7106International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page. Alternatively, a repl

      10/31/24 7:30:00 AM ET
      $NEPH
      Medical/Dental Instruments
      Health Care

    $NEPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Nephros Inc.

      SC 13G - NEPHROS INC (0001196298) (Subject)

      2/3/23 3:15:24 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Nephros Inc.

      SC 13G - NEPHROS INC (0001196298) (Subject)

      2/3/23 3:13:44 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Nephros Inc.

      SC 13G - NEPHROS INC (0001196298) (Subject)

      2/3/23 3:11:33 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care

    $NEPH
    Leadership Updates

    Live Leadership Updates

    See more
    • Nephros Hires Judy Krandel as Chief Financial Officer

      SOUTH ORANGE, NJ, Nov. 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, announced the appointment of Judy Krandel as Chief Financial Officer (CFO), effective today. In this role, Ms. Krandel will be responsible for directing the company's finances and working closely with the Chief Executive Officer (CEO) and Board of Directors to develop and execute Nephros's long-term strategy. Ms. Krandel joins the company with an impressive track record in financial leadership and strategic planning. She brings more than 20 years of experience in asset management, inv

      11/1/23 7:30:00 AM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Appoints Joe Harris to Its Board of Directors

      SOUTH ORANGE, NJ, Sept. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced the appointment of Joe Harris to its Board of Directors. "We are excited that Joe is joining our board," said Andy Astor, President and Chief Executive Officer of Nephros. "He brings years of financial, sales, and marketing acumen to the board, with experience in both large and small healthcare ventures." "I am thrilled to join the Nephros board," said Joe Harris. "I believe Nephros is at an exciting point as they continue to focus on sales moment

      9/8/22 4:00:00 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • RION Appoints Alisa Lask as Chief Commercial Officer

      - Alisa Lask to lead commercialization of the first off-the-shelf exosome therapeutic platform - Two active FDA registrations RION, a biotechnology company headquartered in Rochester, Minnesota pioneering new innovations in exosomes for therapeutic and aesthetic indications, today announced the appointment of Alisa Lask as Chief Commercial Officer. "Alisa brings an exemplary track record gained through both global and U.S. leadership roles at Galderma, Allergan, Zimmer-Biomet, and Eli Lilly and Company, showing significant capability to spearhead commercial strategies to create world-class aesthetic and therapeutic product franchises," said Dr. Atta Behfar, Founder of RION. "She has prov

      1/14/22 9:00:00 AM ET
      $CLGN
      $NEPH
      Industrial Specialties
      Health Care
      Medical/Dental Instruments

    $NEPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $NEPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Krandel Judy

      4 - NEPHROS INC (0001196298) (Issuer)

      3/31/25 4:11:30 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Director Amron Arthur H was granted 22,418 shares, increasing direct ownership by 22% to 125,881 units (SEC Form 4)

      4 - NEPHROS INC (0001196298) (Issuer)

      1/3/25 6:13:00 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Lask Alisa

      4 - NEPHROS INC (0001196298) (Issuer)

      1/3/25 5:08:03 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Amron Arthur H bought $11,176 worth of shares (5,000 units at $2.24), increasing direct ownership by 5% to 103,463 units (SEC Form 4)

      4 - NEPHROS INC (0001196298) (Issuer)

      5/30/24 4:35:22 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Banks Robert R. Jr. bought $112,050 worth of shares (50,000 units at $2.24), increasing direct ownership by 250% to 70,000 units (SEC Form 4)

      4 - NEPHROS INC (0001196298) (Issuer)

      5/16/24 4:49:44 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Amron Arthur H bought $17,130 worth of shares (7,000 units at $2.45) and acquired 91,463 shares (SEC Form 4)

      4 - NEPHROS INC (0001196298) (Issuer)

      3/14/24 4:28:20 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care

    $NEPH
    SEC Filings

    See more
    • SEC Form 10-Q filed by Nephros Inc.

      10-Q - NEPHROS INC (0001196298) (Filer)

      5/15/25 4:00:45 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - NEPHROS INC (0001196298) (Filer)

      5/8/25 4:15:47 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Nephros Inc.

      DEFA14A - NEPHROS INC (0001196298) (Filer)

      4/30/25 4:16:33 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care